Robert Kleiman expands role at ERT

Adds chief medical officer to current role as vp of global cardiology

ERT, a US provider of clinical services and medical devices, has appointed Robert Kleiman as chief medical officer. He will also continue in his current role as vice president of Global Cardiology.

Prior to joining ERT in April 2004, Dr Kleiman had worked for ERT as an independent contractor through his cardiology and cardiac electrophysiology practice since 1994. ERT’s cardiology group has more than tripled in size since 2004.

In addition to his current duties, Dr Kleiman will take an increasing consulting and sales role.

Commenting on his appointment, Dr Kleiman said: ‘I have enjoyed my long association with ERT and very much look forward to working with our customers and staff in my new role of working more closely with sponsors to ensure the efficacy and safety of new drugs.’

You may also like

Regulatory

ERT introduces solution to measure Lung Clearance Index

Solution provides greater data granularity to measure disease progression in respiratory trials where standard spirometry is insufficient
Regulatory

ERT recognised for improving and accelerating clinical research

Company named finalist for PACT Technology Company of the Year Award
Regulatory

Exco InTouch launches Gather and redefines the use of mobile technology in clinical trials

New product suite supports patients, sites and sponsors throughout the clinical journey
Regulatory

Scottish Equity Partners takes minority stake in Exco InTouch

Will provide a initial investment of £3m to accelerate mobile patient communication solutions
Regulatory

Almac and Exco InTouch form alliance

To deliver patient compliance as well as ePRO services using multiple technologies
Regulatory

FDA approves AstraZeneca's Breztri Aerosphere as first single-inhaler triple therapy for asthma

AstraZeneca has received FDA approval to extend Breztri Aerosphere's indication to include maintenance treatment of asthma in patients aged 12 and older, based on Phase III KALOS and LOGOS trial data showing statistically significant improvements in lung function
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Subscribe now